Vericel (VCEL) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vericel Reports Third Quarter 2025 Financial Results
November 6, 2025 7:55 AM ESTRecord Third Quarter Total Revenue of $67.5 Million
MACI Revenue Growth of 25% to $55.7 Million
Net Income of $5.1 Million and Adjusted EBITDA Margin of 25%
Record Third Quarter Operating Cash Flow of $22.1 Million
More than 800 MACI Arthro Surgeons Trained to Date
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn... More
